Henry O. Gosebruch

Chief Strategy Officer at AbbVie, Inc.

Henry O. Gosebruch

Henry O. Gosebruch

Chief Strategy Officer at AbbVie, Inc.

Biography

Henry O. Gosebruch is on the board of Aptinyx, Inc. and Chief Strategy Officer & Executive Vice President at AbbVie, Inc. In his past career Mr. Gosebruch held the position of Co-Head-Mergers & Acquisitions North America at JPMorgan Securities LLC. Henry O. Gosebruch received an undergraduate degree from The Wharton School of the University of Pennsylvania.

Overview
RelSci Relationships

3676

Number of Boards

2

Birthday

1973

Age

47

Contact Data
Trying to get in touch with Henry O. Gosebruch? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Henry O. Gosebruch likely has professional access to. A relationship does not necessarily indicate a personal connection.

President & Chief Executive Officer at Tobira Therapeutics, Inc.

Relationship likelihood: Strong

Chief Financial Officer & Executive Vice President at AbbVie, Inc.

Relationship likelihood: Strong

Chief Executive Officer at AbbVie, Inc.

Relationship likelihood: Strong

Vice Chairman, Healthcare Investment Banking at JPMorgan Chase & Co.

Relationship likelihood: Strong

Former President, Chief Executive Officer & Director at Aptinyx, Inc.

Relationship likelihood: Strong

Director at Legg Mason & Co. LLC

Relationship likelihood: Strong

Vice Chairman, External Affairs & Chief Legal Officer at AbbVie, Inc.

Relationship likelihood: Strong

Vice Chairman & President at AbbVie, Inc.

Relationship likelihood: Strong

Vice Chairman, Chief Commercial Officer at AbbVie, Inc.

Relationship likelihood: Strong

Executive Vice President & Chief Human Resources Officer at AbbVie, Inc.

Relationship likelihood: Strong

Paths to Henry O. Gosebruch
Potential Connections via
Relationship Science
You
Henry O. Gosebruch
Chief Strategy Officer at AbbVie, Inc.
Education
Career History
Chief Strategy Officer
2015 - Current

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the discovery, development, manufacture and sale of a line of proprietary pharmaceutical products. It is focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C and human immunodeficiency virus; neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; as well as other serious health conditions. The company was founded on 2013 and is headquartered in North Chicago, IL.

Co-Head-Mergers & Acquisitions North America
1995 - 2015

J.P. Morgan Securities offers a broad array of investment products and the world’s leading investment managers. These expansive resources—the best people and products in the industry coupled with a Financial Advisor who is directly involved in the investment process—are the true benefits of working with it.

Boards & Committees
Independent Director
2019 - Current
Member of the Advisory Board, Life Sciences & Management Program
Current
Transactions
Details Hidden

AbbVie, Inc. raised money in a private placement transaction

Details Hidden

Allergan Plc purchases Forest Laboratories, Inc.

Details Hidden

Spectrum Pharmaceuticals, Inc. purchases Allos Therapeutics, Inc.

Public Holdings
Restricted data only for RelSci Professional users.
Events
Speaker
Westin New York Grand Central-New York, NY
J.P. Morgan Aviation, Transportation & Industrials Conference

Speaker
New York City, NY
2013 iGlobal Forum Mergers and Acquisitions Investing Summit

Global market conditions are ripe for M&A—cash continues to accumulate on corporate balance sheets, valuations are more reasonable, and private equity firms are looking at a backlog of exits. The one-day Summit will provide a panoramic overview of the global M&A landscape along with a glimpse into what’s on the horizon for 2013 and beyond. It will most importantly provide the perfect platform needed by corporate and private equity investors, hedge funds, investment bankers, lenders and asset managers to meet face-to-face and get deals done.

Speaker
36 Central Park S-New York, NY
2013 iGlobal Forum Mergers and Acquisitions Investing Summit

Global market conditions are ripe for M&A—cash continues to accumulate on corporate balance sheets, valuations are more reasonable, and private equity firms are looking at a backlog of exits. The one-day Summit will provide a panoramic overview of the global M&A landscape along with a glimpse into what’s on the horizon for 2013 and beyond. It will most importantly provide the perfect platform needed by corporate and private equity investors, hedge funds, investment bankers, lenders and asset managers to meet face-to-face and get deals done.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Henry O. Gosebruch. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Henry O. Gosebruch's profile does not indicate a business or promotional relationship of any kind between RelSci and Henry O. Gosebruch.